Anti-AIDS Agents 69. Moronic Acid and Other Triterpene Derivatives as Novel Potent Anti-HIV Agents
Citations Over TimeTop 10% of 2006 papers
Abstract
In a continuing structure-activity relationship study of potent anti-HIV agents, seven new triterpene derivatives were designed, synthesized, and evaluated for in vitro antiviral activity. Among them, moronic acid derivatives 19, 20, and 21 showed significant activity in HIV-1 infected H9 lymphocytes. Compounds 19 and 20 were also evaluated against HIV-1 NL4-3 and drug resistant strains in the MT-4 cell line. Compounds 19 and 20 showed better antiviral profiles than the betulinic acid analogue 8 (PA-457), which has successfully completed a Phase IIa clinical trial. Compound 20 showed potent anti-HIV activity with EC50 values of 0.0085 microM against NL4-3, 0.021 microM against PI-R (a multiple protease inhibitor resistant strain), and 0.13 microM against FHR-2 (an HIV strain resistant to 8). Promising compound 20 has become a new lead for modification, and further development of 20-related compounds as clinical trial candidates is warranted.
Related Papers
- → A Review on Preparation of Betulinic Acid and Its Biological Activities(2021)157 cited
- → Betulinic Acid Derivatives as Anticancer Agents: Structure Activity Relationship(2006)141 cited
- → Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway(2023)13 cited
- Recent Advances of Betulinic Acid and Its Derivatives(2004)
- Synthesis and anti-tumor activity of 30-hydroxy derivatives of 23-hydroxy betulinic acid(2007)